09 Nov 2021 - 31 Mar 2022

Be a part of the latest
Alzheimer's research

See if I'm eligible

Enter your email to take the survey and see if you, or the person you care for, is eligible to take part.

By clicking 'Submit' you agree to our terms of service and our privacy policy . We will keep you in the loop with relevant updates and account-related emails. You can unsubscribe at any time.

Already have a Sano account? Visit the study page

At least 50 million people worldwide are thought to be living with Alzheimer’s disease (the most common form of dementia). Although the biggest risk factor for Alzheimer’s is ageing, the disease is not a normal part of getting older and there are genetic factors at play in some cases.

The goal of this study is to help develop a potential new drug treatment for Alzheimer's disease (AD), which researchers think could be effective in treating AD in its early stages. The drug, ALZ-801, is being developed by Alzheon as a potential new treatment for slowing or stopping cognitive decline in some AD patients.

Eligible participants for the study will receive either the potential new treatment drug or a placebo. The study will also help researchers gather further information about the drug’s long-term safety.

Why take part? 01

If you qualify for and decide to join the APOLLOE4 study, you may receive at no cost:

  • Access to a study drug for 18 months that is designed to slow Alzheimer’s disease progression
  • Close care and monitoring from an Alzheimer’s disease specialist
  • Opportunity to help advance the treatment of Alzheimer’s disease
  • Reimbursement for study-related time and travel expenses

Who can take part? 02

You, or the person you care for, must:

  • Be aged 50 to 80 years old
  • Have a clinical diagnosis of Alzheimer’s disease or mild cognitive impairment
  • Be willing to securely share DNA data
  • Be willing to have DNA data screened for the APOE4 homozygous genotype
  • Be based in the United States

Safety & security 03

When you entrust your DNA Data and Personal Information to Sano Genetics, we commit to keeping them safe and secure. If you consent to participate, the Study Data will be stored by Sano Genetics on secure, encrypted, and wholly owned and secure servers (e.g. HIPAA compliant servers). Every part of Sano is built privacy-first and we use clear, transparent language to keep you informed at every stage throughout the process.

  • Your data belongs to you
  • Industry level encryption
  • Dedicated support
  • Full transparency
  • Free to use and participate
  • Making personalised medicine a reality

Learn more 04

Have questions?

Get in touch